Important results from the project
The project has largely achieved its goals and brought a blood-based test for early detection of pancreatic cancer through clinical validation and to market. The product, manufacturing and quality assurance have been further developed and clinical collaborations have been strengthened. The project has also opened up new indication areas that can broaden the target population and increase clinical value.
Expected long term effects
In the longer term, the project is expected to contribute to the clinical validation of the blood-based test in new international populations and to reach the market. The test may enable earlier detection of pancreatic cancer in defined risk groups, thereby increasing the possibility of treatment and improved survival. The project also creates the conditions for international expansion and broadening to more risk groups.
Approach and implementation
The project was implemented through parallel activities in product development, manufacturing and quality assurance, as well as clinical validation. The work was carried out in close collaboration with clinical, academic and industrial partners. The approach has generally worked well, but some technical development and validation activities took longer than planned and affected the schedule. The collaborations have worked well and have been important for the progress of the project.
The project description has been provided by the project members themselves and the text has not been looked at by our editors.
